161 related articles for article (PubMed ID: 19419863)
1. Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
Tapadar S; He R; Luchini DN; Billadeau DD; Kozikowski AP
Bioorg Med Chem Lett; 2009 Jun; 19(11):3023-6. PubMed ID: 19419863
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel isoxazole-based HDAC inhibitors.
Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
[TBL] [Abstract][Full Text] [Related]
3. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
4. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
Neelarapu R; Holzle DL; Velaparthi S; Bai H; Brunsteiner M; Blond SY; Petukhov PA
J Med Chem; 2011 Jul; 54(13):4350-64. PubMed ID: 21548582
[TBL] [Abstract][Full Text] [Related]
8. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
Bieliauskas AV; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
[TBL] [Abstract][Full Text] [Related]
10. Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
Curtin ML; Garland RB; Heyman HR; Frey RR; Michaelides MR; Li J; Pease LJ; Glaser KB; Marcotte PA; Davidsen SK
Bioorg Med Chem Lett; 2002 Oct; 12(20):2919-23. PubMed ID: 12270175
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
12. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
Guan P; Wang L; Hou X; Wan Y; Xu W; Tang W; Fang H
Bioorg Med Chem; 2014 Nov; 22(21):5766-75. PubMed ID: 25311567
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
14. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
15. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
Dai Y; Guo Y; Guo J; Pease LJ; Li J; Marcotte PA; Glaser KB; Tapang P; Albert DH; Richardson PL; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2003 Jun; 13(11):1897-901. PubMed ID: 12749893
[TBL] [Abstract][Full Text] [Related]
16. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
19. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
20. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]